Theresa M Rossouw
Overview
Explore the profile of Theresa M Rossouw including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
du Toit L, Prinsloo A, Steel H, Feucht U, Louw R, Rossouw T
Viruses
. 2023 Feb;
15(2).
PMID: 36851493
With the global rollout of mother-to-child prevention programs for women living with HIV, vertical transmission has been all but eliminated in many countries. However, the number of children who are...
12.
Richardson S, Kgagudi P, Manamela N, Kaldine H, Venter E, Pillay T, et al.
Cell Rep Med
. 2023 Jan;
4(1):100910.
PMID: 36603577
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4 and BA.5 variants caused major waves of infections. Here, we assess the sensitivity of BA.4 to binding, neutralization, and antibody-dependent...
13.
Theron A, Anderson R, Madzime M, Rossouw T, Steel H, Meyer P, et al.
Molecules
. 2022 Dec;
27(24).
PMID: 36558190
There is increasing awareness of an association between the uptake of the HIV integrase inhibitor, dolutegravir, in first-line antiretroviral regimens with unusual weight gain and development of the metabolic syndrome,...
14.
Madzime M, Theron A, Anderson R, Tintinger G, Steel H, Meyer P, et al.
J Immunotoxicol
. 2022 Nov;
19(1):1-8.
PMID: 36394569
Dolutegravir is a highly potent HIV integrase strand transfer inhibitor that is recommended for first-line anti-retroviral treatment in all major treatment guidelines. A recent study has shown that people taking...
15.
16.
Worsley C, van der Mescht M, Hoffmann D, Meyer P, Ueckermann V, Rossouw T
J Infect
. 2022 Jun;
85(3):334-363.
PMID: 35705136
No abstract available.
17.
Kitchin D, Richardson S, van der Mescht M, Motlou T, Mzindle N, Moyo-Gwete T, et al.
Cell Rep Med
. 2022 Apr;
3(3):100535.
PMID: 35474744
The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding antibody responses...
18.
Richardson S, Madzorera V, Spencer H, Manamela N, van der Mescht M, Lambson B, et al.
Cell Host Microbe
. 2022 Apr;
30(6):880-886.e4.
PMID: 35436444
The SARS-CoV-2 Omicron variant escapes neutralizing antibodies elicited by vaccines or infection. However, whether Omicron triggers cross-reactive humoral responses to other variants of concern (VOCs) remains unknown. We used plasma...
19.
Richardson S, Manamela N, Motsoeneng B, Kaldine H, Ayres F, Makhado Z, et al.
Cell Rep Med
. 2022 Mar;
3(2):100510.
PMID: 35233544
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VOCs) exhibit escape from neutralizing antibodies, causing concern about vaccine effectiveness. However, while non-neutralizing cytotoxic functions of antibodies are associated with...
20.
Rossouw T, Anderson R, Manga P, Feldman C
Front Immunol
. 2022 Feb;
13:776861.
PMID: 35185878
Cardiovascular dysfunction and disease are common and frequently fatal complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Indeed, from early on during the SARS-CoV-2 virus pandemic it was...